Bavarian Nordic Provides Clarification on the HERA Framework Agreement and the Public Preparedness Business
COPENHAGEN, Denmark, November 1, 2025 – Bavarian Nordic A/S hereby issues the…
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ in Elderly and Updates to the Prescribing Information
Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext…
Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University of Tbingen
TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT)…
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced…
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
Saint-Herblain (France), June 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris:…